postpartum hemorrhage

A 2024 Louisiana law reclassified misoprostol, a drug used to treat postpartum hemorrhages and in medical abortions, as a controlled substance, requiring hospitals to store it securely instead of in emergency carts. This change delays access to the drug during emergencies, increasing risks for patients with conditions like asthma or high blood pressure who rely on misoprostol as their primary hemorrhage treatment option.

Louisiana's 2024 law reclassified misoprostol as a controlled substance, requiring it to be stored securely and delaying access during emergencies. This has increased hemorrhage risks for pregnant patients, as misoprostol is a critical, cost-effective drug for treating postpartum hemorrhage and has other reproductive healthcare uses.

Louisiana's 2024 law reclassifying misoprostol as a controlled substance forced hospitals to store it securely, delaying access during emergencies. The drug is critical for treating pregnancy-related hemorrhages but is now harder to retrieve, increasing patient risk. The law also reclassified mifepristone, further complicating reproductive healthcare access.

Philadelphia nurses and researchers are developing a tool called Vasowatch to more accurately predict postpartum hemorrhage by tracking heart rate during contractions, addressing gaps in current risk assessments that often misclassify women as low risk. The tool aims to improve maternal health outcomes by identifying myometrial fatigue, a precursor to excessive bleeding after childbirth.

A wellness influencer died from a postpartum hemorrhage during a home birth, a complication deemed 'eminently treatable' but rare in hospitals. Paramedics found they could not detect her blood pressure, and postpartum hemorrhage occurs in 1-5% of births.